Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NLSP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.85% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.69M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.04 | 52 Weeks Range 1.30 - 10.14 | Updated Date 06/29/2025 |
52 Weeks Range 1.30 - 10.14 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) -862.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14854260 | Price to Sales(TTM) - |
Enterprise Value 14854260 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.02 | Shares Outstanding 4908030 | Shares Floating 1687887 |
Shares Outstanding 4908030 | Shares Floating 1687887 | ||
Percent Insiders 32.46 | Percent Institutions 10.04 |
Analyst Ratings
Rating 1 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG is a Swiss biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. Founded in 2015, NLS is dedicated to addressing unmet medical needs and improving the lives of individuals affected by these conditions.
Core Business Areas
- Central Nervous System Disorders: NLS Pharmaceutics focuses on developing treatments for rare and complex CNS disorders, including narcolepsy, idiopathic hypersomnia (IHS) and attention deficit hyperactivity disorder (ADHD).
Leadership and Structure
Alex Zwyer is the Chief Executive Officer. The organizational structure includes departments focused on research and development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Mazindol CR: Mazindol CR is a product that NLS has licensed from the Swiss Company, A.P.A. AG, and is developing for ADHD. The company plans to initiate a Phase 2 trial. Market share data is not yet available, but current competitors are Teva Pharmaceuticals (TEVA) and Tris Pharma.
- Quilienceu00ae: Quilience (mazindol ER) is a product being developed for the treatment of narcolepsy. The company plans to initiate a Phase 3 trial. Market share data is not yet available, but current competitors are Jazz Pharmaceuticals (Jazz), Avadel Pharmaceuticals (AVDL), and Harmony Biosciences (HRMY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and long development timelines. There is a growing demand for innovative therapies for CNS disorders.
Positioning
NLS Pharmaceutics is positioned as a company specializing in treatments for rare and complex CNS disorders with a focus on developing novel therapies. Its advantage is its focus on unmet needs and a commitment to innovation.
Total Addressable Market (TAM)
The total addressable market for narcolepsy and ADHD is substantial. Analysts estimate the narcolepsy market to reach billions of dollars in coming years, while the ADHD market is already a multi-billion dollar market. NLS Pharmaceutics aims to capture a portion of these markets with its novel therapies.
Upturn SWOT Analysis
Strengths
- Specialized focus on CNS disorders
- Novel therapy development
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- High reliance on clinical trial outcomes
Opportunities
- Partnerships and collaborations
- Successful clinical trial results
- Expansion into new markets
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Funding risks
Competitors and Market Share
Key Competitors
- JAZZ
- AVDL
- HRMY
- TEVA
Competitive Landscape
NLS Pharmaceutics faces competition from established pharmaceutical companies with greater resources and broader product portfolios. However, its focus on specific CNS disorders provides a niche advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are limited due to the company's early stage.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals of its product candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials and seeking partnerships to support development and commercialization.
Summary
NLS Pharmaceutics is a development-stage company focusing on innovative therapies for CNS disorders. The company's success depends on positive clinical trial results, regulatory approvals, and successful commercialization. Limited financial resources and competition from established players pose challenges. The company has a niche advantage due to its focus on underserved areas. The company's early stage warrants cautious investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Third-party market research
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is based on estimations and may vary. All data is as of the current date and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.